2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the …

RA Byrne, X Rossello, JJ Coughlan… - … Heart Journal: Acute …, 2024 - academic.oup.com
2023 ESC Guidelines for the management of acute coronary syndromes Page 1 2023 ESC
Guidelines for the management of acute coronary syndromes Developed by the task force on …

2024 ESC Guidelines for the management of elevated blood pressure and hypertension: Developed by the task force on the management of elevated blood pressure …

JW McEvoy, CP McCarthy, RM Bruno… - European Heart …, 2024 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

2024 ESC Guidelines for the management of chronic coronary syndromes: Developed by the task force for the management of chronic coronary syndromes of the …

C Vrints, F Andreotti, KC Koskinas… - European heart …, 2024 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) …

IC Van Gelder, M Rienstra, KV Bunting… - European Heart …, 2024 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled …

EM Apperloo, BL Neuen, RA Fletcher… - The Lancet Diabetes & …, 2024 - thelancet.com
Background SGLT2 inhibitors and GLP-1 receptor agonists both improve cardiovascular and
kidney outcomes in patients with type 2 diabetes. We sought to evaluate whether the …

Prevention of Cardiovascular Disease in Type 1 Diabetes

C Manrique-Acevedo, IB Hirsch… - New England Journal of …, 2024 - Mass Medical Soc
Prevention of Cardiovascular Disease in Type 1 Diabetes | New England Journal of Medicine
Skip to main content The New England Journal of Medicine homepage Advanced Search …

The role of multimorbidity in patients with heart failure across the left ventricular ejection fraction spectrum: Data from the Swedish Heart Failure Registry

D Tomasoni, C Vitale, F Guidetti… - European Journal of …, 2024 - Wiley Online Library
Aims The aim of this analysis was to provide data on the overall comorbidity burden, both
cardiovascular (CV) and non‐CV, in a large real‐world heart failure (HF) population across …

[HTML][HTML] Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in …

I Lingvay, J Deanfield, SE Kahn, PE Weeke… - Diabetes …, 2024 - diabetesjournals.org
OBJECTIVE To evaluate the cardiovascular effects of semaglutide by baseline glycated
hemoglobin (HbA1c) and change in HbA1c in a prespecified analysis of Semaglutide Effects …

Western diets and chronic diseases

TE Adolph, H Tilg - Nature Medicine, 2024 - nature.com
Abstract 'Westernization', which incorporates industrial, cultural and dietary trends, has
paralleled the rise of noncommunicable diseases across the globe. Today, the Western-style …

Trends in cardiovascular disease incidence among 22 million people in the UK over 20 years: population based study

N Conrad, G Molenberghs, G Verbeke, F Zaccardi… - bmj, 2024 - bmj.com
Objective To investigate the incidence of cardiovascular disease (CVD) overall and by age,
sex, and socioeconomic status, and its variation over time, in the UK during 2000-19. Design …